Martin Höglund

Uppsala University — Sweden

Medicine · Health Sciences

50h-index12.5kcitations269works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(97), Chronic Myeloid Leukemia Treatments(96), Chronic Lymphocytic Leukemia Research(73), Acute Lymphoblastic Leukemia research(54), Myeloproliferative Neoplasms: Diagnosis and Treatment(22)

Publications268 total

Single-cell multi-omics uncovers differentiation-dependent transcriptional programs shaping epigenetic subgroups in AML
Blood·2025
A human pan-disease blood atlas of the circulating proteome
Science·2025· 16 citedOpen Access
High Prevalence of Psychological Symptoms, Sexual Dysfunction, and Prolonged Medical Leave Two Years After Acute Leukemia Diagnosis—Patient Reported Outcome in Sweden
eJHaem·2025Open Access
Second‐ and Third‐Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory <scp>AML</scp>—A Population‐Based Study
European Journal Of Haematology·2025Open Access
Supplementary Figure 3 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Supplementary Figure 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Supplementary Table 4 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Supplementary Figure 5 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Supplementary Table 1 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Data from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Supplementary Figure 1 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Supplementary Figure 4 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Supplementary Table 3 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Supplementary Table 2 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Supplementary Figure 6 from Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
2025Open Access
Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study
Clinical Cancer Research·2025· 1 citedOpen Access
Essai de phase III randomisé COMMODORE 2 : résultats d’une étude multicentrique évaluant crovalimab vs éculizumab chez des patients atteints d’hémoglobinurie paroxystique nocturne (HPN) naïfs de traitement par un inhibiteur du complément
La Revue de Médecine Interne·2024
Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
Blood·2024· 1 citedOpen Access
Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab
Blood·2024Open Access
Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling
Blood·2024Open Access
page 1 of 14Next →

Frequent Co-authors

Gunnar Juliusson(14), Sören Lehmann(12), Lars Möllgård(10), Leif Stenke(9), Vladimir Lazarević(9), Ulla Olsson‐Strömberg(9), Johan Richter(9), Åsa Rangert Derolf(7), Dick Stockelberg(7), Anders Wåhlin(7), Kimmo Porkka(7), Stefan Deneberg(7), Lovisa Wennström(7), Berit Markevärn(7), Petar Antunović(6), Magnus Björkholm(6), Perttu Koskenvesa(6), Satu Mustjoki(6), Henrik Hjorth‐Hansen(6), Arta Dreimane(6)